-continued

```
<211> LENGTH: 7
<212> TYPE: PRT
<213 > ORGANISM: Artificial Sequence
<220> FEATURE:
<223 > OTHER INFORMATION: FMC63 LC-CDR2
<400> SEQUENCE: 46
His Thr Ser Arg Leu His Ser
<210> SEQ ID NO 47
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223 > OTHER INFORMATION: FMC63 LC-CDR3
<400> SEQUENCE: 47
Gln Gln Gly Asn Thr Leu Pro Tyr Thr
                5
```

1-191. (canceled)

- **192.** A method for assessing cell surface glycans, the method comprising:
 - (a)(i) incubating a test composition comprising a plurality of cells under conditions to release one or more glycans from the surface of cells in the test composition, wherein a sample comprising one or more cell surface glycans is generated and (a)(ii) determining the presence, absence, identity and/or level of glycans present in the sample, thereby assessing the cell surface glycan profile of the sample; or
 - (b) determining the presence, absence, identity and/or level of glycans present in a sample, thereby assessing the cell surface glycan profile of the sample, wherein the sample comprises one or more glycans released from the surface of cells present in a test composition comprising a plurality of cells after incubation of the test composition under conditions to release the one or more glycans.
- 193. The method of claim 192, wherein cells in the test cell composition comprise whole cells or intact cells.
- **194**. The method of claim **192**, wherein the test cell composition comprises between 1×10^6 cells and 5×10^6 cells, inclusive.
- 195. The method of claim 192, wherein the test cell composition comprises a concentration of between 1×10^5 cells/mL and 1×10^8 cells/mL, inclusive, between 1×10^6 cells/mL and 5×10^7 cells/mL, inclusive, or between 5×10^6 cells/mL and 2.5×10^7 cells/mL, inclusive.
- 196. The method of claim 192, wherein the incubation is carried out in the presence of an N-glycosidase.
- **197**. The method of claim **196**, wherein the N-glycosidase is a peptide N-glycosidase (PNGase) F.
- 198. The method of claim 197, wherein the PNGase F is recombinant.
- **199**. The method of claim **197**, wherein the PNGase F comprises a PGNase F of *Flavobacterium meningosepticum*, or a portion or mutant thereof that is enzymatically active.
- **200**. The method of claim **197**, wherein the PNGase F comprises the amino acid sequence set forth in SEQ ID NO: 1 or a portion or mutant thereof that is enzymatically active,

- or an amino acid sequence that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%. 92%. 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:1 or is a portion thereof that is enzymatically active.
- **201**. The method of claim **197**, wherein the PNGase F comprises the amino acid sequence set forth in SEQ ID NO: 1.
- **202.** The method of claim **197**, wherein the amount of PNGase F is 1 unit to 5000 units, inclusive.
- 203. The method of claim 192, wherein the incubating the test composition is for an amount of time that between or between about 5 minutes and 12 hours, 30 minutes and 6 hours or 1 hour and 3 hours, each inclusive.
- 204. The method of claim 192, wherein the incubating the test composition is at a temperature between 25 $^{\circ}$ C. and 39 $^{\circ}$ C. or between 35 $^{\circ}$ C. and 39 $^{\circ}$ C.
- 205. The method of claim 192, wherein, prior to the determining the presence, absence, identity and/or level of glycans present in a sample, the method further comprises labeling glycans from the sample with a detectable label.
- 206. The method of claim 205, wherein the detectable label is a fluorescent label and the fluorescent label is or comprises 2-aminobenzamide (2-AB), 2-aminobenzoic acid (2-AA), 2-aminopyridine (PA), 2-Aminoacridone (AMAC), 2-aminonaphthalene trisulfonic acid (ANTS), and 1-aminopyrene-3,6,8-trisulfonic acid (APTS), 3-(Acetylamino)-6-aminoacridin (AA-Ac), 6-Aminoquinoline (6-AQ), 7-Aminomethyl-coumarin (AMC), 2-Amino (6-amido-biotinyl) pyridine (BAP), 9-Fluorenylmethoxycarbonyl (FMOC)-hydrazide, 1,2-Diamino-4,5-methylenedioxy-benzene (DMB), or o-Phenylenediamine (OPD).
- 207. The methods of claim 206, wherein the fluorescent label comprises a carbamate tagging group, a quinolone fluorophore, and a tertiary amine.
- 208. The method of claim 192, wherein, prior to determining the presence, absence, identity and/or level of the one or more glycans, the sample is subjected to glycan purification or enrichment.